scholarly journals Relationship of Adherence to Cervical Cancer Treatment Guideline Towards Patients’ Five-year Survival: Systematic Review of Follow-up Trials

2020 ◽  
Vol Volume 12 ◽  
pp. 12649-12655
Author(s):  
Novianti Qurnia Putri ◽  
Tiara Bunga Mayang Permata ◽  
Ni Ayu Wulandari ◽  
. Handoko ◽  
Endang Nuryadi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cervical Cancer ◽  
Cancer Treatment ◽  
Treatment Guideline ◽  
Relationship Of

scholarly journals Treatment Compliance as a Major Barrier to Optimal Cervical Cancer Treatment in Guatemala

2019 ◽  
pp. 1-5 ◽  
Author(s):  
Abigail S. Zamorano ◽  
Joaquin Barnoya ◽  
Eduardo Gharzouzi ◽  
Camaryn Chrisman Robbins ◽  
Emperatriz Orozco ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Access To Care ◽  
Cancer Treatment ◽  
Patient Population ◽  
Treatment Compliance ◽  
External Beam Radiation ◽  
Cervical Cancer Patient ◽  
Beam Radiation ◽  
Lost To Follow Up

PURPOSE Despite being the only hospital to provide comprehensive cervical cancer treatment to many medically underserved Guatemalan women, no assessment of the cervical cancer patient population at the Guatemala Cancer Institute has been performed. To understand the demographics of the patient population, their treatment outcomes, and access to care, we sought to assess treatment compliance of patients with cervical cancer at the Guatemala Cancer Institute and its effects on patient outcomes. METHODS A retrospective chart review was conducted of patients with cervical cancer between 2005 and 2007 and assessed for follow-up through December 2015. Demographics and clinical characteristics were tabulated. A Kaplan-Meier curve to model compliance was generated. RESULTS Ninety-two patients with invasive cancer were analyzed. Most presented with squamous cell carcinoma (73%) and at locally advanced stages (IIB, 51%; IIIB, 33%). Most (75 of 92, 81.5%) initiated treatment after diagnosis, but 18.5% (17 of 92) were lost to follow-up before treatment initiation. For treatment, 97% received external beam radiation, 84% brachytherapy, and 4% concomitant chemotherapy. Nearly 20% of patients were lost to follow-up in the first 6 months and 65% in the first 5 years. Of the 67 patients who completed treatment, only 15 (16% of the initial cohort) were diagnosed with a recurrence. No deaths were recorded. CONCLUSION The low recurrence rate and no documented deaths suggest a correlation with the low compliance rate and poor follow-up. This finding highlights the need to examine more fully the barriers to compliance and access to care among this population to optimize the treatment of cervical cancer.

Follow-up for women after treatment for cervical cancer: A systematic review

2009 ◽  
Vol 114 (3) ◽  
pp. 528-535 ◽  
Author(s):  
Laurie Elit ◽  
Anthony W. Fyles ◽  
Michaela C. Devries ◽  
Thomas K. Oliver ◽  
Michael Fung-Kee-Fung
Keyword(s):  
Systematic Review ◽  
Cervical Cancer

scholarly journals Evaluation of patient involvement in a systematic review and meta-analysis of individual patient data in cervical cancer treatment

2012 ◽  
Vol 1 (1) ◽  
Author(s):  
Claire L Vale ◽  
Jayne F Tierney ◽  
Nicolette Spera ◽  
Andrea Whelan ◽  
Alison Nightingale ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cervical Cancer ◽  
Cancer Treatment ◽  
Patient Involvement ◽  
Individual Patient Data ◽  
Meta Analysis ◽  
Patient Data

scholarly journals A prospective study of demographic features and quality of life in HIV-positive women with cervical cancer treated at Tygerberg Hospital

2015 ◽  
Vol 16 (1) ◽  
Author(s):  
George Du Toit ◽  
Martin Kidd
Keyword(s):  
Quality Of Life ◽  
Cervical Cancer ◽  
Cancer Treatment ◽  
Hiv Positive ◽  
Hiv Positive Women ◽  
Eortc Qlq C30 ◽  
Eortc Qlq ◽  
Hiv Negative

Background: Cervical cancer and human immunodeficiency virus (HIV) infection/acquired immune deficiency syndrome (AIDS) both have a high incidence in South Africa. Cervical cancer treatment of HIV-positive women poses challenges. Treatment-related changes in quality of life (QOL) of such women are important to future treatment protocols.Aim: To examine demographic data of HIV-negative and HIV-positive women at diagnosis of cervical cancer and describe their changes in QOL as a result of treatment.Methods and materials: All newly diagnosed patients with cervical cancer at Tygerberg Hospital were approached to participate in the study. The European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) and the Cervix Cancer Module (QLQ-CX24) were used. General QOL was measured with the EORTC QLQ-C30 and cervical-specific QOL with the QLQ-CX24 questionnaire. The patients completed the questionnaire at diagnosis, on completion of treatment and at 3 months’ follow-up.Results: The study included a total of 221 women of whom 22% were HIV-positive; the latter were younger and of higher educational level than the rest. Mean monthly income and stage distribution was similar between the two groups. HIV-positive patients underwent radiation therapy more commonly than chemoradiation. HIV-positive women showed statistically significantly higher loss to follow-up during the study. HIV-positive women experienced no improvement in insomnia, appetite loss, nausea, vomiting, diarrhoea, social role or any of the sexual domains. In contrast, HIV-negative women experienced statistically significant improvement in all sexual domains other than sexual/vaginal functioning. The QOL improvement of HIV-negative women was statistically significantly greater than their HIV-positive counterparts in the majority of QOL domains. Global health improved in both groups, with HIV-negative women experiencing greater improvement. HIV-positive women experienced an initial decline of peripheral neuropathy (PN) symptoms post treatment with a return to pretreatment values at 3 months’ follow-up. The change in PN was statistically significant between the HIV-negative and HIV-positive women.Conclusion: Demographic differences exist between the HIV-negative and HIV-positive groups. The differential outcome in the QOL of HIV-positive and HIV-negative women treated for cervical cancer might be related to persistence of AIDS-related symptoms on completion of cervical cancer treatment.

scholarly journals Adjuvant Hysterectomy for Cervical Cancer Patients Treated with Chemoradiation Therapy: A Systematic Review on the Pathology-Proven Residual Disease Rate

Cancers ◽  
2021 ◽  
Vol 13 (24) ◽  
pp. 6190
Author(s):  
Kim van Kol ◽  
Renée Ebisch ◽  
Jurgen Piek ◽  
Maaike Beugeling ◽  
Tineke Vergeldt ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cervical Cancer ◽  
Survival Rate ◽  
Residual Disease ◽  
Survival Rates ◽  
Chemoradiation Therapy ◽  
Disease Rate ◽  
Cochrane Database ◽  
Adjuvant Hysterectomy

Objective: To determine the incidence of pathology-proven residual disease in adjuvant hysterectomy specimens in patients with cervical cancer, treated with chemoradiation therapy. Secondly, to assess a possible association for pathology-proven residual disease regarding the time between chemoradiation therapy and adjuvant hysterectomy. Additionally, the survival rate and complication rate were assessed. Methods: PubMed, EMBASE, and the Cochrane database were searched from inception up to 8 March 2021. Results: Of the 4601 screened articles, eleven studies were included. A total of 1205 patients were treated with chemoradiation therapy and adjuvant hysterectomy, ranging from three to twelve weeks after chemoradiation therapy. A total of 411 out of 1205 patients (34%) had pathology-proven residual disease in the adjuvant hysterectomy specimen. There was no association found in the time between chemoradiation therapy and adjuvant hysterectomy. Follow-up ranged from 2.4 to 245 months, during which 270 patients (22%) relapsed, and 298 patients (27%) were deceased. A total of 202 (35%) complications were registered in 578 patients. Conclusion: there is no association found in the time between chemoradiation therapy and residual disease on adjuvant hysterectomy specimens. The survival rates after chemoradiation therapy and adjuvant hysterectomy are suboptimal, while the risk of complications after adjuvant hysterectomy is high.

X-ray treatment for uterine cervix cancers

1927 ◽  
Vol 23 (11) ◽  
pp. 1181-1181
Author(s):  
H. Martius
Keyword(s):  
Cervical Cancer ◽  
Cancer Treatment ◽  
Uterine Cervix ◽  
X Ray ◽  
Current State

The author summarizes the current state of the issue of cervical cancer treatment with Rntgen's and radium rays. At 5-year follow-up, this treatment yields, according to different authors, from 40.5 to 55.6% of permanent cures in operable cases and from 10.2 to 16.6% in non-operable cases.

Quality of life and sexual functioning after cervical cancer treatment: a long-term follow-up study

2009 ◽  
Vol 18 (5) ◽  
pp. 476-482 ◽  
Author(s):  
Elfriede R. Greimel ◽  
Raimund Winter ◽  
Karin S. Kapp ◽  
Josef Haas
Keyword(s):  
Quality Of Life ◽  
Cervical Cancer ◽  
Cancer Treatment ◽  
Sexual Functioning ◽  
Follow Up Study ◽  
Long Term Follow Up

scholarly journals Follow-up for cervical cancer: a Program in Evidence-Based Care systematic review and clinical practice guideline update

2016 ◽  
Vol 23 (2) ◽  
pp. 109 ◽  
Author(s):  
L. Elit ◽  
E.B. Kennedy ◽  
A. Fyles ◽  
U. Metser
Keyword(s):  
Systematic Review ◽  
Cervical Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guideline ◽  
Evidence Based ◽  
Dna Testing ◽  
Hpv Dna ◽  
Hpv Dna Testing ◽  
Evidence Based Care

Background In 2009, the Program in Evidence-based Care (pebc) of Cancer Care Ontario published a guideline on the follow-up of cervical cancer. In 2014, the pebc undertook an update of the systematic review and clinical practice guideline for women in this target population.Methods The literature from 2007 to August 2014 was searched using medline and embase [extended to 2000 for studies of human papillomavirus (hpv) dna testing]. Outcomes of interest were measures of survival, diagnostic accuracy, and quality of life. A working group evaluated the need for changes to the earlier guidelines and incorporated comments and feedback from internal and external reviewers.Results One systematic review and six individual studies were included. The working group concluded that the new evidence did not warrant changes to the 2009 recommendations, although hpv dna testing was added as a potentially more sensitive method of detecting recurrence in patients treated with radiotherapy. Comments from internal and external reviewers were incorporated.Recommendations Summary Follow-up care after primary treatment should be conducted and coordinated by a physician experienced in the surveillance of cancer patients. A reasonable follow-up strategy involves visits every 3–4 months within the first 2 years, and every 6–12 months during years 3–5. Visits should include a patient history and complete physical examination, with elicitation of relevant symptoms. Vaginal vault cytology examination should not be performed more frequently than annually. Combined positron-emission tomography and computed tomography, other imaging, and biomarker evaluation are not advocated; hpv dna testing could be useful as a method of detection of recurrence after radiotherapy. General recommendations for follow-up after 5 years are also provided. 

Sign in / Sign up

Export Citation Format

Share Document